The Impact on Big Pharma’s Production Model of Medicine Policies in a Context of Austerity in France and the UK

Philippe Abecassis () and Nathalie Coutinet ()
Additional contact information
Philippe Abecassis: CEPN - Centre d'Economie de l'Université Paris Nord - UP13 - Université Paris 13 - USPC - Université Sorbonne Paris Cité - CNRS - Centre National de la Recherche Scientifique, ACT - Analyse des Crises et Transitions - LABEX ICCA - UP13 - Université Paris 13 - Université Sorbonne Nouvelle - Paris 3 - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité - Université Sorbonne Paris Nord - Université Sorbonne Paris Nord
Nathalie Coutinet: CEPN - Centre d'Economie de l'Université Paris Nord - UP13 - Université Paris 13 - USPC - Université Sorbonne Paris Cité - CNRS - Centre National de la Recherche Scientifique, ACT - Analyse des Crises et Transitions - LABEX ICCA - UP13 - Université Paris 13 - Université Sorbonne Nouvelle - Paris 3 - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité - Université Sorbonne Paris Nord - Université Sorbonne Paris Nord

Post-Print from HAL

Abstract: The austerity policies implemented by France and the United Kingdom since the 2008 crisis have led to a drastic rationalisation of health spending in both countries. This is especially true for spending on medicines, which is an important part of the health budget. Even though health policies in the two countries seem to be very different, given the specificities of each health system, this rationalisation has expressed itself through greater privatisation, a hardening of mechanisms for controlling the prices of the most expensive drugs and incentives to use the cheapest drugs when possible, such as generic drugs. The pharmaceutical industry has not suffered much from these measures. It first reacted, at least provisionally, by accepting to develop generic drugs. As of 2012, Big Pharma companies have started to implement a new model for producing innovation and highly expensive drugs, grounded in biotechnology and customised medicine. This strategy is based on highly outsourced industrial organisations which have allowed the industry to benefit from healthcare systems, to reduce risks and to make large profits.

Keywords: drug policy pharmaceutical pricing Big Pharma blockbuster custombuster generic drug; drug policy; pharmaceutical pricing; Big Pharma; blockbuster; custombuster; generic drug (search for similar items in EconPapers)
Date: 2017-10-01
Note: View the original document on HAL open archive server: https://hal.science/hal-04368126v1
References: Add references at CitEc
Citations:

Published in 2017, ⟨10.4000/osb.1935⟩

Downloads: (external link)
https://hal.science/hal-04368126v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04368126

DOI: 10.4000/osb.1935

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().